Allyx Therapeutics Announces Positive Phase 1b Multiple Ascending Dose Data and Advances ALX-001 to Patients
NEW HAVEN, Conn., March 11, 2024 (GLOBE NEWSWIRE) -- Allyx Therapeutics, a clinical-stage biotechnology company, announced that its lead compound, ALX-001, is ready to proceed to Phase 2 clinical development in Alzheimer’s and Parkinson’s disease. This announcement was made in conjunction with the presentation of positive findings from the company’s Phase 1b multiple ascending dose study at the AD/PD™ 2024 Conference in Lisbon. ALX-001 is a highly selective, first-in-class, synapse-targeted, disease-modifying oral therapy in development for neurodegenerative diseases.
- This announcement was made in conjunction with the presentation of positive findings from the company’s Phase 1b multiple ascending dose study at the AD/PD™ 2024 Conference in Lisbon.
- ALX-001 is a highly selective, first-in-class, synapse-targeted, disease-modifying oral therapy in development for neurodegenerative diseases.
- The multiple ascending dose study (NCT05804383) examined the safety, tolerability and pharmacokinetics of twice-daily oral doses of ALX-001 in 32 heathy adult participants aged 50-80.
- Allyx Therapeutics has initiated a 28-day safety study of ALX-001 in Alzheimer’s disease patients (NCT05804383) and is initiating a study in Parkinson’s disease patients.